ESR1 and breast cancer: Here, we provide evidence that, in contrast to TNBC, activated GR in endocrine therapy-resistant ER+ breast cancer acts as an estrogen receptor silencer (ERS) that inhibits liver metastatic outgrowth by suppressing ESR1 expression.